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(4) Abstract 
Stroke incidence is high in end-stage renal disease and risk factors differ between 
the dialysis and general populations. However, risk factors and outcomes following 
renal transplantation remain unclear. 
We analysed all adult patients with a functioning renal transplant from 01/01/2007 to 
31/12/2012. Data were extracted from the electronic patient record. Variables 
associated with stroke were identified by survival analyses; demographic, clinical, 
imaging and laboratory variables were assessed and case-fatality determined. 
Follow-up was until 05/12/2013.  
956 patients were identified (median age 40.1 years, 59.9% male). Atrial fibrillation 
prevalence was 9.2% and 38.2% received a transplant during follow-up. 26 (2.7%) 
experienced a stroke during 4409 patient-years of follow-up (84.6% ischemic). 
Stroke incidence was 5.96/1000 patient-years. Factors associated with stroke on 
regression analysis were prior stroke, diabetes, age, systolic hypertension and 
hemoglobin. Atrial fibrillation was associated with time to stroke (p<0.001).Warfarin 
did not associate with ischemic stroke risk in those with AF.  Fatality was 19.2% at 7, 
23.1% at 28 and 42.3% 365 days after stroke.  
Patients with a functioning renal transplant have a high stroke incidence and case-
fatality. Unlike those on hemodialysis, risk factors are similar to the general 
population.  We did not demonstrate benefit from warfarin use in those with AF.  
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Introduction 
End-stage renal disease (ESRD) is associated with increased cardiovascular 
morbidity and mortality[1] - an effect which is reduced but not obliterated by renal 
transplantation. In the last two decades, much attention has turned toward 
cerebrovascular disease and its complications in those with ESRD. A recent report 
has provided insight into the relevance of stroke affecting those with ESRD in the 
21st century. Compared to the general population stroke incidence was found to be 
6-fold greater and - of concern - younger patients were more likely to be affected[2]. 
It is recognised that effective preventive strategies are urgently needed.  
Patients undergoing renal replacement therapy (RRT) experience a unique 
physiological environment where the conventional, general population-based, stroke 
risk factors are not consistently found to be associated with stroke[3]. For instance, 
although atrial fibrillation (AF) is a common finding in patients on hemodialysis the 
effect of AF on stroke risk remains unclear[4] and is further complicated by the 
absence of clear benefit from warfarin use[5,6]. Furthermore, vitamin K antagonists 
(warfarin) are associated with significant side effects, beyond that of bleeding in 
patients on hemodialysis, including accelerated vascular calcification[7]. Fortunately, 
the risk of stroke in those on the transplant waiting list can be reduced by receiving a 
renal transplant with sustained transplant function[8]. However, the assumption that 
return of “normal” renal function will produce stroke risk factors similar to those of the 
general population and provide benefit from their preventive strategies is unproven.  
The goal of our study was to; 1) describe the incidence of stroke in those with a 
functioning renal transplant; 2) examine risk factors associated with stroke with 
particular interest in the effect of AF and warfarin use; and 3) describe outcomes 
following stroke.   
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Methods 
 
All adult patients attending Glasgow Renal and Transplant Unit with a functioning 
renal transplant for ESRD between 1st January 2007 and 31st December 2012 were 
identified using the electronic patient record (EPR), (Strathclyde Electronic Renal 
Patient Record, Vitalpulse, UK). All laboratory and imaging results within the west of 
Scotland are imported to this database improving capture of investigations and 
follow-up. Cohort entry was recorded as 1st January 2007 in those patients with a 
functioning transplant at study inception, or from date of transplantation.  Clinical and 
demographic details at cohort entry were recorded including primary renal diagnosis, 
presence of diabetes, cardiovascular disease, cerebrovascular disease, AF and 
history of antithrombotic drug use. We also extracted blood hemoglobin, serum 
albumin, phosphate, adjusted calcium, creatinine and urinary protein to creatinine 
ratio from 90 to 180 days following cohort entry. Patient postcode was used to assign 
a deprivation category using the Scottish Index of Multiple Deprivation (SIMD). The 
SIMD is a relative ranking of all areas of Scotland produced by the Scottish 
Government[9] which uses a multidimensional model to assess deprivation using 38 
indicators across seven domains; employment, income, health, education, crime, 
housing and geographic access to services. Deprivation quintiles were calculated 
and cases were subdivided into most deprived (quintiles 1 and 2) and least deprived 
(quintiles 3-5).       
 
Outcomes and definition of stroke 
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The time to first stroke in those with a functioning renal transplant after cohort entry 
was recorded. Date of death was recorded and fatality expressed at 7, 28 and 365 
days following stroke. Stroke was defined from the EPR as either 1) a new clinical 
diagnosis of stroke recorded in the diagnostic timeline, 2) the presence of ischemic 
or hemorrhagic stroke on brain imaging associated with a clinical history of new 
neurological deficit or stroke, or 3) any of cerebrovascular disease, cerebrovascular 
accident, cerebral infarct, subarachnoid hemorrhage or intracerebral hemorrhage 
listed on death certificate as a primary or major contributory factor to a patient death. 
All events were reviewed by 2 independent clinicians (M.D.F., P.B.M.) with cases 
adjudicated by a third observer (P.T.) where disagreement arose. Subdural and 
extradural hemorrhages were excluded. 
 
Statistical analysis 
Follow up data were available to December 5th 2013. Patient follow up was censored 
at transplant failure (death or return to dialysis). Baseline demographics were 
compared using Mann-Whitney U test or Chi-square test as appropriate. Kaplan-
Meier survival analysis was performed for time to first ischemic stroke. Cox 
regression analyses were performed to identify significant independent risk factors 
for stroke and a backward stepwise regression was performed to identify significantly 
influential variables (defined as p<0.1) for use in the final multivariable model. To 
assess risk factors for first ever stroke, we removed all cases with a prior history of 
cerebrovascular disease and repeated the analyses. The effect of stroke on mortality 
was assessed using a multivariable Cox regression, adjusted for age, sex, RRT 
vintage, systolic blood pressure, serum creatinine and prior cardiovascular disease. 
Data were analysed using SPSS version 21 (IBM, Armonk, New York). 
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Ethical approval 
The west of Scotland ethics committee officer waived the need for ethical committee 
review on the basis that this was analysis of routine clinical data. Caldicott Guardian 
approval was granted by the information governance manager of NHS Greater 
Glasgow and Clyde. 
 
Results 
 
A total of 956 patients with a renal transplant were included; 591(61.8%) had a 
functioning transplant at the time of study inception and 365(38.2%) received a 
transplant during the study period. The mean age at commencing RRT for ESRD 
was 40.1 years, 383 (40.1%) were female and 88 (9.2%) had a history of AF. The 
median dialysis vintage was 8.77 years [IQR 3.20,16.35] 128 (13.4%) patients 
returned to dialysis during follow up. Censoring for death or return to dialysis, median 
follow-up for the cohort was 5.4 (IQR 2. 3, 6.9) years.  
 
Incidence and outcomes 
26 patients (2.7% [95% CI 1.7-3.7%]) experienced a new stroke event over 4409 
patient-years of follow up. 24 patients (92.3%) had brain imaging performed as part 
of diagnostic assessment, with the remainder considered to have a diagnosis of 
stroke based on the death certification. The majority (84.6%) of events were 
ischemic. Stroke incidence was 5.96/1000 patient-years.  There were 186 deaths 
during follow-up and 157 deaths in those with a functioning transplant. Analyzing 
only cases of death with a functioning transplant the cause of death was 
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cardiovascular in 29.3% (46) of cases, infection in 28% (44), malignancy in 21.7% 
(34) and other causes in 35% (55). There were no cases of SAH in patients with 
autosomal dominant polycystic kidney disease (ADPKD). Baseline differences 
between patients who suffered stroke and patients who did not are described in table 
1. 
 
Survival analyses of variables associated with risk of stroke 
Uni-variable regression analyses of all patients revealed significance (p<0.05) for 
age, presence of prior cerebrovascular disease, diabetes, AF and higher systolic 
blood pressure.  Multivariable analysis was performed using variables identified as 
significant following backward stepwise regression (p<0.1). This revealed significant 
independent associations for stroke as age, presence of diabetes and prior 
cerebrovascular disease (table 2). We removed cases with prior stroke from the 
analysis to assess factors associated with first ever stroke and refit a backwards 
stepwise regression model. This revealed that prior diabetes (Hazard ratio (HR) 
3.64, 95% CI 1.21 – 10.91. p=0.021) and higher hemoglobin (HR 1.04, 95% CI 1.00 
– 1.07. p=0.026) were independently associated with stroke. Kaplan-Meier survival 
analysis of time to ischemic stroke in those with and without AF demonstrated a 
significant association between presence of AF and stroke, p<0.001 (figure 1). In 
patients with AF, warfarin use had no significant effect on time to stroke, p 0.573 
(figure 2).  
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Outcome in patients following stroke 
15 of 26 (57.7%) died during follow-up. Cardiovascular causes accounted for 75% of 
deaths (53.3% directly attributed to cerebrovascular disease). All-cause mortality 
was significantly higher following stroke (57.7% vs 18.4%, adjusted HR 2.08 [95% CI 
1.17, 3.69], p=0.013).  Fatality was 19.2% at 7 days, 23.1% at 28 days and 42.3% at 
1 year. Assessing only those with first ever stroke, 60% (9) died on follow-up with 7, 
28 and 365 day fatality of 26.7%, 33.3% and 40% respectively. Comparison of 
groups dead vs. alive at the end of follow-up is shown in supplementary table s1.  
 
 
Discussion 
 
Renal transplantation is the gold standard treatment for patients with ESRD[10]. 
Whilst it is recognised that reducing cardiovascular risk factors at all stages of CKD 
is important[11],  the benefit of targeted therapies requires clarification in ESRD. We 
have described the incidence, associations of and outcomes following stroke in 
those with a functioning renal transplant in the west of Scotland over a 6-year period. 
Our large single centre study describes a high stroke incidence, presence of 
conventional cardiovascular risk factors and, most striking, fatality outcomes worse 
than that expected in the general population. Further to this, although AF was 
associated with time to ischemic stroke, the key prevention strategy – warfarin – was 
not associated with benefit in our cohort.   
 
Incidence  
The incidence of cerebrovascular disease increases with worsening renal function 
and peaks at ESRD[12].  Of concern, previous reports have suggested that the 
initiation of dialysis itself may cause stroke[3].  Renal transplantation improves 
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patient outcomes by reducing risk of cardiovascular related death[13,14] however, 
the effect of transplantation on stroke risk has only recently been described[8]. In this 
retrospective USRDS review the authors describe that renal transplantation predicts 
a 34% reduction in risk of subsequent cerebrovascular events compared to 
remaining on the transplant waiting list. They describe an incidence of 24.6 
cerebrovascular events/1000 patient-years in those who receive a renal transplant 
compared to 45.6 events/1000 patient years in those remaining on the waiting list. In 
another USRDS review a more recent study[15] presented an event incidence of 7.4 
ischemic strokes/1000 patient years. This apparent difference in rates can be 
explained by different selection criteria but more so by the definition of 
cerebrovascular events between the two studies. The report with the higher 
incidence included all of ischemic stroke, hemorrhagic stroke and TIA rather than 
strictly ischemic stroke. With focus on the UK population, we have recently reported 
the stroke incidence of those receiving maintenance hemodialysis for ESRD as 
41.5/1000 patient years[6] – a result significantly higher than the observed rate in the 
transplant population. Our present study has described the incidence within a well-
defined population, observing an incidence rate of 5.96 cerebrovascular events/1000 
patient-years – greater than twice the underlying incidence of stroke in the general 
population for Scotland[16]. Although high, we note this is lower than the only other 
UK published study describing incidence at 12.4/1000 patient years[17]. Whereas we 
report incidence of stroke in all patients attending our unit, the other study 
retrospectively assessed only those who were selected for a steroid-sparing 
immunosuppressant regime. The two studies’ populations are therefore affected by 
this bias; for example pre-existing ischemic heart disease and diabetes were greater 
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in their population compared to ours (14.8% and 25.4% v 7% and 17.2% 
respectively).  
 
Stroke risk factors 
Previous retrospective studies have attempted to clarify the risk factors underpinning 
stroke[18,19] in the ESRD population. Surprisingly, conventional risk factors such as 
hypertension, hyperlipidemia and AF are not consistently associated with stroke risk 
in those receiving dialysis. Conversely in the transplant population, described risk 
factors mimic those seen in the general population.  Older age, diabetes, 
hypertension and AF are consistent findings on multivariable analyses[15,17,20,21]. 
Assessing our cohort as a whole we discovered age, prior stroke, diabetes, higher 
systolic blood pressure and AF were associated with stroke on univariable 
regression.  Multivariable analysis found diabetes, systolic BP, age and prior stroke 
were significantly associated with stroke. Excluding cases with prior stroke we found 
that higher hemoglobin and presence of diabetes were independently associated 
with stroke. Serum creatinine was not associated with stroke. Using Kaplan-Meir 
survival analyses, we demonstrated a significant association between presence of 
AF and stroke, although we could not demonstrate a significant influence of warfarin 
on stroke in those with AF (figures 1 and 2).   
 
Outcomes 
All-cause mortality was significantly higher following stroke. An adjusted 
multivariable Cox regression analysis demonstrated a significant association 
between stroke and time to death. Further, case fatality (death within first 7 days) 
following stroke was high and early outcomes were worse in those with first ever 
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stroke. Our findings reveal that fatality rates are higher than the background 
population and more in keeping with those reported in the dialysis population[22]. 
Whilst it is inevitable that suffering a stroke will negatively impact survival, the 
similarity of reported outcomes to those who remain on dialysis is notable and 
suggest an effect of ESRD which is not reduced by transplantation. 
 
Study limitations 
We describe the incidence, associations and outcomes of stroke in a large single 
centre renal transplant unit encompassing 956 patients over 4409 years of patient 
follow-up. Despite our large sample size and completeness of follow-up we do 
recognize the following limitations. As a retrospective study we can only describe 
association and not causation. The small number of strokes in the group of those  
receiving a transplant following a period on dialysis limits our ability to detect 
associations on multivariable regression – specifically, we acknowledge that the 
relatively low number of stroke events may lead to type 2 errors in our analyses, 
which may explain the absence of effect from atrial fibrillation on multivariable 
analysis.  We have not included data on immunosuppressive medication, although 
we acknowledge recent evidence suggesting steroid use independently increases 
the risk of CVA[17]. Finally, important data were not available which may offer an 
explanation for the lack of effect from warfarin. For example, we are unable to 
comment on cases where warfarin was discontinued and the lack of INR reporting 
limits comment about time in the therapeutic range.  
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Conclusion 
The incidence of stroke in those with a functioning renal transplant is higher than the 
background population, but markedly lower than those on hemodialysis. Stroke in 
transplant recipients is associated with similar conventional risk factors observed in 
the general population, but it remains unclear if reversal of modifiable factors can 
reduce stroke risk. Of primary interest, although AF is associated with time to stroke, 
prior warfarin use did not confer protection in this study. Further, the outcomes 
following stroke are dismal – resembling those who remain on dialysis. Dedicated 
trials for stroke therapies are needed in the transplant population to determine the 
reversibility of the increased stroke risk and the effects on outcomes.  
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 No Stroke n=930 Ischemic Stroke n=22 Hemorrhagic Stroke n =4 P value (IS vs No Stroke) 
 
Median age at starting RRT [IQR] 
 
39.7 [29.2,50.5] 
 
44.1 [35.6,51.7] 
 
45.9.0 [41.0,61.0] 
 
0.22 
Female (%) 373 (40.1%) 10 (45.5%) 0 0.613 
PRD n (%) 
    Diabetic Nephropathy 
    Interstitial disease 
    SLE/HUS 
    PCKD 
    Reno-vascular disease 
    GN 
    Other 
    Missing 
 
73 (7.8) 
129(13.9) 
14(1.5) 
87 (9.4) 
24(2.6) 
182(19.6) 
36 (3.9) 
385 (41.4) 
 
1 (4.5) 
0 
1 (4.5) 
3 (13.6) 
0 
2 (9.1) 
3 (13.6) 
12 (54.5) 
 
1 (25) 
- 
- 
- 
1 (25) 
1 (25) 
1 (25) 
- 
0.079 
RRT vintage, years; Median [IQR] 8.57 [3.16,16.19] 12.06 [8.80,19.91] 7.13 [2.68,16.80] 0.017 
     
Prior CeVD (%) 30 (3.2) 9 (40.9) 3 (75) <0.001 
Prior CVD (%) 64 (6.9) 3(13.6) 0 0.221 
Prior DM (%) 153 (16.5) 9 (40.9) 2 (50) 0.003 
Prior AF (%) 81 (8.7) 6 (27.3) 1 (25) 0.003 
Warfarin (%) 131 (14.1) 5 (22.7) 1 (25) 0.252 
Antiplatelet (%) 636 (68.4) 16 (72.7) 4 (100) 0.665 
     
Hb, g/L; Median [IQR] 12.4 [11.2,13.6] 12.7 [11.2,14.6] 13.1 [12.1.13.7] 0.227 
Albumin, g/L; Median [IQR] 38.0 [36.0,40.0] 37.0 [35.0,39.0] 38.0 [37.5.41.0] 0.126 
SCr, µmol/L; Median [IQR] 135.0 [107.0,173.0] 134.0 [121.0,161.0] 136.5 [115.151.5] 0.652 
AdCal, mmol/L; Median [IQR] 2.4 [2.4,2.6] 2.5  [2.3,2.5] 2.5 [2.4.2.7] 0.429 
PO4, mmol/L; Median [IQR] 0.9 [0.7,1.1] 0.9 [0.9,1.1] 1.0 [0.8.1.2] 0.106 
SBP, mmHg; Median [IQR] 140.0 [128.0,153.0] 149.0 [140.0,155.0] 159.5 [145.5.163.0] 0.152 
DBP, mmHg; Median [IQR] 79.0 [72.0,86.0] 81.0 [74.0,89.0] 82.0 [79.0.89.0] 0.670 
uPCR, mg/mmol; Median [IQR] 19.8 [8.9,47.1] 27.0 [9.7,80.0] 8.8 [4.4.47.1] 0.350 
 
Death (%) 
 
142 (15.3) 
 
12 (54.5) 
 
3 (75) 
 
<0.001 
     
SIMD most deprived (%) 448 (48.6) 14 (63.6) 2 (50) 0.163 
     
 
Table 1.Characteristics of all transplant recipients, Stroke vs no stroke, split by stroke subtype. Abbreviations used in the table; IS = Ischemic stroke, RRT = 
Renal Replacement Therapy, PRD = Primary Renal Diagnosis, SLE = Systemic Lupus Erythematosis, HUS = Hemolytic uraemic syndrome, PCKD = 
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Polycystic Kidney Disease, GN = Glomerulonephritis, CeVD = Cerebrovascular disease, CVD = Cardiovascular disease, DM = Diabetes Mellitus, AF = Atrial 
Fibrillation, Hb = Hemoglobin, SCr = serum creatinine, AdCal = Adjusted serum calcium, PO4 = serum phosphate, SBP = systolic blood pressure, DBP = 
diastolic blood pressure, uPCR = urinary protein:creatinine ratio, SIMD = Scottish Index of Multiple Deprivation. 
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Univariable                                                                          Multivariable 
 
Variable HR p 95% CI Variable HR p value 95% CI 
Age 1.04 0.010 1.01 – 1.07 Age 1.04 0.034 1.00 – 1.08 
Female 0.89 0.766 0.40 – 1.96     
DM 3.68 0.001 1.69 – 8.00 DM 2.29 0.041 1.04 – 5.05 
CeVD 23.73 <0.001 10. 91 – 51.63 CeVD 19.81 <0.001 8.98 – 43.72 
CVD 1.37 0.607 0.41 – 4.57     
SBP (mmHg) 1.02 0.044 1.00 – 1.04     
DBP (mmHg) 1.02 0.229 0.99 – 1.07     
AF 4.59 0.001 1.92 – 10.94     
Warfarin 2.06 0.122 0.83 – 5.12     
Antiplatelet 1.72 0.242 0.69 – 4.3     
Hb (g/L) 1.01 0.332 0.99 – 1.03     
Albumin (g/L) 0.94 0.134 0.86 – 1.02     
SCr (µmol/L) 0.996 0.380 0.99 – 1.00     
AdCal (mmol/L) 0.57 0.641 0.05 – 6.2     
PO4 (mmol/L) 2.80 0.151 0.69 – 11.4     
uPCR (mg/mmol) 1.00 0.336 0.998 – 1.00     
RRT Vintage 1.0 0.157 1.0-1.0     
Deprivation 1.82 0.136 0.83 – 4.0     
 
 
 
Table 2 All transplant recipients. Variables entered into the multivariable analysis were selected 
following backward stepwise regression, using variables with p<0.1. Abbreviation used in the table; 
DM = Diabetes Mellitus, CeVD = Cerebrovascular disease, CVD = Cardiovascular disease, SBP = 
systolic blood pressure, DBP = diastolic blood pressure, AF = atrial fibrillation, Hb = hemoglobin, SCr 
= serum creatinine, AdCal = adjusted serum calcium, PO4 = serum phosphate, uPCR = urinary 
protein:creatinine ratio. 
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Figure 1 Time to ischemic stroke  – AF v no AF in all transplant recipients, p <0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Time to ischemic stroke in patients with AF, warfarin v no warfarin, p=0.573 
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SUPPLEMENTARY TABLES 
 
 
 
 
 Alive n=799 Dead n=157 P value 
 
Median Age at Starting RRT [IQR] 
 
39.0 [28.0,48.6] 
 
45.4 [32.9,55.2] 
 
<0.001 
Female (%) 322 (40.3) 61 (38.9)  0.735 
PRD Diagnosis, n (%) 
    Diabetic Nephropathy 
    Interstitial disease 
    SLE/HUS 
    PCKD 
    RVD 
    GN 
    Other 
    Missing 
 
62 (7.8) 
115 (14.4) 
13(1.6) 
75 (9.4) 
15(1.9) 
170(21.3) 
32 (4) 
317 (39.7) 
 
13 (8.3) 
14 (8.9) 
2 (1.3) 
15 (9.6) 
10 (6.4) 
15 (9.6) 
7 (4.5) 
81 (51.6) 
 
 
 
 
 
 
 
 
<0.001 
Median RRT Vintage; years [IQR] 7.45 [2.79,15.14] 14.18 [8.15,20.89] <0.001 
    
Prior CeVD (%) 28 (3.5) 14 (8.9) 0.002 
Prior CVD (%) 46 (5.8) 21 (13.4) 0.001 
Prior DM (%) 134 (16.8) 30 (19.1) 0.478 
Prior AF (%) 55 (6.9) 33 (21) <0.001 
Warfarin (%) 106 (13.3) 31 (19.7) 0.034 
Antiplatelet (%) 529 (66.2) 127 (80.9) <0.001 
    
Hb, g/dL [IQR] 124 [112,136] 124.0[111,137] 0.729 
Albumin, g/L [IQR] 39.0 [36,41] 37.0 [33,39] <0.001 
SCr, µmol/L [IQR] 133.0 [107,165] 152.0 [152,113] 0.003 
AdCal, mmol/L [IQR] 2.5 [2.4,2.6] 2.5 [2.4,2.5] 0.047 
PO4, mmol/L [IQR]  0.9 [0.7,1.1]  1.0 [0.9,1.2] <0.001 
SBP, mmHg [IQR] 140 [127,152] 142.5 [130,157] 0.037 
DBP, mmHg [IQR] 79.0 [72,86] 80.0 [70,84] 0.230 
uPCR, mg/mmol [IQR] 18.9 [8.4,41.3] 35.1 [12.99,83.3] <0.001 
    
    
SIMD most deprived  383 [48.3] 81 [52.3] 0.367 
    
 
Table s1 All transplant recipients, Dead v alive during follow-up.  Abbreviations used in the table; 
RRT = Renal Replacement Therapy, PRD = Primary Renal Diagnosis, SLE = Systemic Lupus 
Erythematosis, HUS = Hemolytic uraemic syndrome, PCKD = Polycystic Kidney Disease, GN = 
Glomerulonephritis, CeVD = Cerebrovascular disease, CVD = Cardiovascular disease, DM = 
Diabetes Mellitus, AF = Atrial Fibrillation, Hb = Hemoglobin, SCr = serum creatinine, AdCal = 
Adjusted serum calcium, PO4 = serum phosphate, SBP = systolic blood pressure, DBP = diastolic 
blood pressure, uPCR = urinary protein:creatinine ratio, SIMD = Scottish Index of Multiple 
Deprivation. 
